Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study

被引：0
|
作者：
Fumiko Yamamoto
Yuriko Unno
Tomoo Okamura
Rie Ikeda
Kaori Ochiai
Naoyuki Hayashi
机构：
[1] Nippon Boehringer Ingelheim Co.,Medicine Division
[2] Ltd.,PMS Division
[3] EPS Corporation,undefined
来源：
Diabetes Therapy | 2020年 / 11卷
关键词：
DPP-4 inhibitor; Japanese; Linagliptin; Long-term; Post-marketing surveillance; Type 2 diabetes mellitus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：107 / 117
页数：10
相关论文
共 50 条
  • [1] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes Mellitus: A 3-Year Post-Marketing Surveillance Study
    Yamamoto, Fumiko
    Unno, Yuriko
    Okamura, Tomoo
    Ikeda, Rie
    Ochiai, Kaori
    Hayashi, Naoyuki
    DIABETES THERAPY, 2020, 11 (01) : 107 - 117
  • [2] Long-term safety and effectiveness of linagliptin by baseline body mass index in Japanese patients with type 2 diabetes: a 3-year post-marketing surveillance study
    Yabe, Daisuke
    Yamamoto, Fumiko
    Lund, Soren S.
    Okamura, Tomoo
    Kadowaki, Takashi
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1303 - 1313
  • [3] Long-term safety and effectiveness of linagliptin as add-on therapy in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance
    Ito, Tomohiro
    Naito, Yusuke
    Shimmoto, Naoki
    Ochiai, Kaori
    Hayashi, Naoyuki
    Okamura, Tomoo
    EXPERT OPINION ON DRUG SAFETY, 2021, 20 (03) : 363 - 371
  • [4] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
    Yamamoto, Fumiko
    Ikeda, Rie
    Ochiai, Kaori
    Hirase, Tetsuaki
    Hayashi, Naoyuki
    Okamura, Tomoo
    DIABETES THERAPY, 2020, 11 (02) : 523 - 533
  • [5] Long-Term Safety and Effectiveness of Linagliptin in Japanese Patients with Type 2 Diabetes and Renal Dysfunction: a Post-Marketing Surveillance Study
    Fumiko Yamamoto
    Rie Ikeda
    Kaori Ochiai
    Tetsuaki Hirase
    Naoyuki Hayashi
    Tomoo Okamura
    Diabetes Therapy, 2020, 11 : 523 - 533
  • [6] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
    Sakae Tanaka
    Hideki Mizutani
    Eri Tsuruya
    Ryoko Fukuda
    Kiyoka Kuge
    Naoki Okubo
    Journal of Bone and Mineral Metabolism, 2021, 39 : 463 - 473
  • [7] Long-term safety and effectiveness of denosumab in Japanese patients with osteoporosis: 3-year post-marketing surveillance study
    Tanaka, Sakae
    Mizutani, Hideki
    Tsuruya, Eri
    Fukuda, Ryoko
    Kuge, Kiyoka
    Okubo, Naoki
    JOURNAL OF BONE AND MINERAL METABOLISM, 2021, 39 (03) : 463 - 473
  • [8] Safety and effectiveness of empagliflozin in Japanese patients with type 2 diabetes: final results of a 3-year post-marketing surveillance study
    Kaku, Kohei
    Yamamoto, Kazuhiro
    Fukushima, Yumiko
    Lliev, Hristo
    Yasui, Atsutaka
    EXPERT OPINION ON DRUG SAFETY, 2022, 21 (10) : 1315 - 1328
  • [9] Real-World Evidence for Long-Term Safety and Effectiveness of Ipragliflozin in Japanese Patients with Type 2 Diabetes Mellitus: final Results of a 3-Year Post-Marketing Surveillance Study (STELLA-LONG TERM)
    Nakamura, Ichiro
    Maegawa, Hiroshi
    Tobe, Kazuyuki
    Uno, Satoshi
    EXPERT OPINION ON PHARMACOTHERAPY, 2021, 22 (03) : 373 - 387
  • [10] Safety and effectiveness of ipragliflozin in Japanese patients with type 2 diabetes mellitus and impaired renal function: subgroup analysis of a 3-year post-marketing surveillance study (STELLA-LONG TERM)
    Kazuyuki Tobe
    Hiroshi Maegawa
    Ichiro Nakamura
    Satoshi Uno
    Diabetology International, 2021, 12 : 181 - 196
12345